Liposomal bupivacaine for treating postoperative pain [ID3799]
Proposed [GID-TA10681] Expected publication date: TBC
Search results
157 results
-
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Proposed [GID-TA10720] Expected publication date: TBC
-
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Proposed [GID-TA10605] Expected publication date: TBC
-
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]
Proposed [GID-TA10655] Expected publication date: TBC
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]
Proposed [GID-TA10660] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Proposed [GID-TA10764] Expected publication date: TBC
-
Semaglutide for managing overweight and obesity [ID3850]
Proposed [GID-TA10765] Expected publication date: TBC
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]
Proposed [GID-TA10782] Expected publication date: 20 October 2021
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Proposed [GID-TA10666] Expected publication date: 26 August 2021
-
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]
Proposed [GID-TA10676] Expected publication date: TBC
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Proposed [GID-TA10763] Expected publication date: TBC
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777
Proposed [GID-TA10810] Expected publication date: 22 October 2021
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
Proposed [GID-TA10749] Expected publication date: TBC
-
Lasmiditan for treating acute migraine [ID3759]
Proposed [GID-TA10807] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
Proposed [GID-TA10505] Expected publication date: 10 August 2022
-
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]
Proposed [GID-TA10753] Expected publication date: TBC
-
Upadacitinib for treating active ankylosing spondylitis [ID3848]
Proposed [GID-TA10735] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Proposed [GID-TA10811] Expected publication date: TBC
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
Proposed [GID-TA10812] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Proposed [GID-TA10813] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Proposed [GID-TA10814] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]
Proposed [GID-TA10815] Expected publication date: TBC
-
Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]
Proposed [GID-TA10816] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
Proposed [GID-TA10817] Expected publication date: TBC
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Proposed [GID-TA10706] Expected publication date: 20 October 2021
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
Proposed [GID-TA10658] Expected publication date: 20 October 2021
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC
-
Maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage: interventional procedure consultation
We are listening to your views on this interventional procedures guidance. Comments close 25 March 2021.
-
Sapropterin for treating phenylketonuria [ID1475]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 18 March 2021.
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
Proposed [GID-TA10719] Expected publication date: TBC
-
Transcatheter Mitral Valve In Ring (TMVIR) for treating a failing mitral valve repair: interventional procedure consultation
We are listening to your views on this interventional procedures guidance. Comments close 25 March 2021.
-
Transapical transcatheter mitral valve-in-valve implantation for a failed surgically-implanted mitral valve bioprosthesis: interventional procedure consultation
We are listening to your views on this interventional procedures guidance. Comments close 25 March 2021.
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Proposed [GID-TA10519] Expected publication date: TBC
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
Proposed [GID-TA10600] Expected publication date: 22 December 2021
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 05 March 2021.
-
Nitisinone for treating alkaptonuria [ID2691]
Proposed [GID-TA10659] Expected publication date: TBC
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
Proposed [GID-TA10802] Expected publication date: TBC
-
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]
Proposed [GID-TA10803] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]
Proposed [GID-TA10804] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Proposed [GID-TA10791] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Proposed [GID-TA10795] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
Proposed [GID-TA10792] Expected publication date: TBC
-
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]
Proposed [GID-TA10796] Expected publication date: TBC
-
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]
Proposed [GID-TA10793] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Proposed [GID-TA10797] Expected publication date: TBC
-
Brolucizumab for treating diabetic macular oedema [ID3902]
Proposed [GID-TA10794] Expected publication date: TBC
-
Faricimab for treating diabetic macular oedema [ID3899]
Proposed [GID-TA10798] Expected publication date: TBC
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
Proposed [GID-TA10799] Expected publication date: TBC